Twist Bioscience finds new SARS-CoV-2 neutralizers
Twist Bioscience has identified immunoglobulin G antibodies and single dose domain VHH nanobodies that have neutralizing effects against SARS-CoV-2. Read More
BioReference debuts NGS tumor profiling assay
Opko Health's BioReference Laboratories and its specialty oncology division GenPath have launched a next-generation (NGS) assay that enables DNA mutational profiling of tumor samples. Read More
BrickBio advances conjugation platform for therapeutic development
BrickBio has demonstrated the power of its conjugation platform process for the commercial development of biologics in-house and with pharmaceutical partners. Read More
Gyros launches new product to support cell & gene therapy manufacturing
Gyros Protein Technologies introduced a new product for adeno-associated virus vector titer determination. Read More
Leica inks distribution deal with MellingMedical
Microscope and image analysis technology developer Leica Microsystems has signed a distribution agreement with the federal health facility supplier MellingMedical. Read More
Orpheris launches phase II trial for COVID-19 immunotherapy
Orpheris said that the first patients have been enrolled in a phase II trial to assess its OP-101 compound for treating hospitalized adults with severe COVID-19. Read More
Unum Therapeutics transfers BOXR cell-based therapy to Sotio
Unum Therapeutics has sold its Bolt-on Chimeric Receptor (BOXR) cell-based therapy technology to immuno-oncology firm Sotio. Read More
Cartesian begins trial of RNA-based cell therapy for COVID-19
Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), including ARDS caused by COVID-19. Read More
Gilead licenses immunotherapy from Jounce
Gilead Sciences has exclusively licensed the JTX-1811 novel cancer immunotherapy program from Jounce Therapeutics. Read More
AstraZeneca begins phase III trial of its COVID-19 vaccine
AstraZeneca has begun a multisite phase III clinical trial evaluation of its investigational COVID-19 vaccine, AZD1222. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
